BACTI_B: EBITDA remained positive as revenues dipped, with strong growth in wound management and new cardiology initiatives

About this update from Bactiguard Holding Ab

Q2 2025 saw continued EBITDA profitability and improved net loss, despite a 14% revenue decline due to delayed BD market launches and currency effects. Hydrocyn Aqua drove strong wound management growth, and early feasibility work in cardiology was initiated. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bactiguard Holding Ab